<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970291</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-01-1-08</org_study_id>
    <nct_id>NCT03970291</nct_id>
  </id_info>
  <brief_title>Impact of NOL Intraoperative Guided Fentanyl Analgesia vs SCC for Elective Major Abdominal Surgery</brief_title>
  <official_title>Impact of Nociceptive-Level (NOL) Intraoperative Guided Fentanyl Analgesia Versus Standard Clinical Care (SCC) for Elective Major Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medasense Biometrics Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medasense Biometrics Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, a newly developed index, the Nociceptive Level (NOL) index, was validated and&#xD;
      showed superiority over heart rate and blood pressure for recognition and grading of intense&#xD;
      and mild nociceptive stimuli during surgery under general anesthesia.&#xD;
&#xD;
      We hypothesize that compared with standard management, NOL-guided anesthesia will lead to&#xD;
      reduced postoperative pain scores, and during anesthesia, to increased hemodynamic stability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uncontrolled postoperative pain may result in significant clinical, psychological, and&#xD;
      socioeconomics consequences. Not only does inadequate pain management following surgery&#xD;
      result in increased morbidity and mortality but it also may delay recovery, result in&#xD;
      unanticipated readmissions, decrease patient satisfaction, and lead to chronic persistent&#xD;
      postsurgical pain. Pain is multifactorial in nature and understanding both the complexity of&#xD;
      pain and its side effects is imperative to achieve a successful surgical outcome.&#xD;
&#xD;
      Nociception/analgesia are currently assessed by monitoring changes in heart rate (HR), blood&#xD;
      pressure (BP), and other indirect parameters which are not sensitive or specific to&#xD;
      nociception. As a result, the patient may be given insufficient analgesia which can promote&#xD;
      postoperative pain, or excessive analgesia which can result in overdosing and related&#xD;
      complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>Through study completion, about 8 months</time_frame>
    <description>Change in pain score in the PACU using the visual analog scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypotension episodes</measure>
    <time_frame>Through study completion, about 8 months</time_frame>
    <description>Change of hypotension episodes (MAP &lt; 55 mmHg and/or &lt; 60 mmHg) during the maintenance period until reversal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inadequate analgesia/anesthesia events</measure>
    <time_frame>Through study completion, about 8 months</time_frame>
    <description>Change in frequency of Inadequate analgesia/anesthesia events*</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total intraoperative fentanyl</measure>
    <time_frame>Through study completion, about 8 months</time_frame>
    <description>Change in total intraoperative fentanyl consumption (in mcg).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Nociceptive-Level (NOL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Analgesic component of anesthesia (fentanyl) will be guided using NOL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Clinical Care (SCC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Clinical Care guided fentanyl administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PMD-200</intervention_name>
    <description>The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)</description>
    <arm_group_label>Nociceptive-Level (NOL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years old.&#xD;
&#xD;
          2. ASA I-III&#xD;
&#xD;
          3. Elective major laparoscopic abdominal surgical, urologic or gynecologic procedures&#xD;
             under general anesthesia.&#xD;
&#xD;
          4. Patient able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any type of anesthesia other than general anesthesia (neuraxial, epidural&#xD;
             analgesia or local regional anesthesia, e.g. transversus abdominal plane block)&#xD;
&#xD;
          2. Patients with rhythm other than sinus cardiac rhythm, implanted pacemakers,&#xD;
             α2-adrenergic agonists and β1-adrenergic antagonists&#xD;
&#xD;
          3. Pregnancy/lactation&#xD;
&#xD;
          4. Central nervous system disorder (neurologic/head trauma/uncontrolled epileptic&#xD;
             seizures)&#xD;
&#xD;
          5. Abuse of alcohol or illicit drugs within the last 6 months&#xD;
&#xD;
          6. Chronic pain conditions - pain in 1 or more anatomic regions that persists or recurs&#xD;
             for longer than 3 months and is associated with significant emotional distress or&#xD;
             significant functional disability.&#xD;
&#xD;
          7. Opioid tolerant - if for at least 1 week the patient has been receiving oral morphine&#xD;
             60 mg/day; transdermal fentanyl 25 mcg/hour; oral hydromorphone 8 mg/day; oral&#xD;
             oxymorphone 25 mg/day; or an equianalgesic dose of any other opioid&#xD;
&#xD;
          8. Chronic use of psychoactive drugs within 90 days prior to surgery&#xD;
&#xD;
          9. Allergy or intolerance to any of the study drugs&#xD;
&#xD;
         10. History of severe cardiac arrhythmias within the last 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Rivka Leah Fuica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

